National Institutes of Health

Description

The purpose of this Funding Opportunity Announcement (FOA) is to continue follow-up of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort through a cooperative agreement. TODAY was a multi-center controlled clinical trial examining the efficacy of three approaches to treat recently diagnosed type 2 diabetes in youth ages 10-17 years. TODAY demonstrated that combination therapy with metformin plus rosiglitazone sustained glycemic control longer than either metformin plus an intensive lifestyle program or metformin alone.TODAY study results also suggest that type 2 diabetes is more aggressive when it occurs at a young age. The primary purpose of this FOA is to continue follow-up of the TODAY cohort to define the long-term clinical course of youth-onset type 2 diabetes.

Who can apply

• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV